Amgen 2002 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2002 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 72

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72

Page 14
opportunity Markets for breakthrough therapeutics can emerge
rapidly once efficacy is demonstrated, potentially affecting the lives of mil-
lions. Nowhere is this clearer than in the global cancer care market, where
Amgen’s latest generation of anemia- and infection-fighting therapeutics
are redefining standards of practice and improving patient lives.
oncology
Cancer remains one of the world’s biggest medical challenges. More than eight million
people worldwide are diagnosed with some form of the disease each year, a number that
continues to rise in step with global population growth and longer life expectancies. Yet
cancer treatments are also growing in effectiveness, improving survival rates for many patients.
Chemotherapy often plays a central role.
Amgen has launched two new therapeutics into the global cancer care marketplace that
are having a meaningful impact on treatment standards in the delivery of chemotherapy to
cancer patients.
Aranesp
®
(darbepoetin alfa), Amgen’s latest anemia treatment, was approved in 2002 in
the United States, Europe, and Australia for the treatment of chemotherapy-related anemia.
Aranesp
®
is a recombinant erythropoietic protein, that is, a protein that stimulates produc-
tion of oxygen-carrying red blood cells. Aranesp
®
has demonstrated an ability to increase red
blood cell count and maintain target hemoglobin levels in cancer patients undergoing